A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)

Inclusion criteria: * Body mass index (BMI) of 18 to ≤37 kg/m\^2 * Diagnosis of chronic HCV infection * Must be infected with HCV GT1a, GT1b, or GT3 Exclusion criteria: * Co-infection with GT1 and GT3 HCV * History of stroke, chronic seizures, or major neurological disorder * History of clinically significant endocrine, gastrointestinal (excepting HCV infection), cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities or diseases * History of neoplastic disease * Positive Hepatitis B surface antigen * History of human immunodeficiency virus (HIV) infection or positive HIV serology * Major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks prior * History of significant multiple and/or severe allergies (including latex allergy), or anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food * Current regular user (including "recreational use") of any illicit drugs or history of drug (including alcohol) abuse within approximately 2 months * Evidence or history of chronic hepatitis not caused by HCV including but not limited to non-HCV viral hepatitis, non-alcoholic steatohepatitis (NASH), drug-induced hepatitis, autoimmune hepatitis * Previous treatments(s) with nonstructural 5A (NS5A) protein inhibitors * Treatment with protease inhibitor(s) \<30 days prior to study enrollment * Previous exposure to interferon-alpha and/or ribavirin within 3 months prior to the first dose of MK-8325 in the study * Clinical or laboratory evidence of advanced or decompensated liver disease; evidence of bridging fibrosis or higher grade fibrosis (Metavir score ≥3) from prior liver biopsy